Novo Nordisk Faces FDA Warning Over Plainsboro Site Inspection
Novo Nordisk announced receiving a warning letter from the FDA following an inspection at its Plainsboro site. The company has devised a corrective action plan, keeping the FDA informed. Novo Nordisk believes this will not impact its production or forecasts shared earlier in the year.
Novo Nordisk has come under scrutiny as the U.S. Food and Drug Administration issued a warning letter following an inspection at its Plainsboro facility.
The Danish pharmaceutical giant responded swiftly with a corrective and preventative action plan, regularly updating the FDA on its progress and expressing confidence in resolving the issues raised.
Despite the challenges, Novo Nordisk does not anticipate any negative effects on its manufacturing or on previously announced forecasts for the year.
ALSO READ
-
Novo Nordisk Addresses FDA Concerns with Action Plan
-
Current Health Headlines: New Moves in Medical Education, Drug Production, and FDA Warnings
-
Roche and Novo Nordisk Compete for Weight Loss Market Lead
-
Abbott and Novo Nordisk Join Forces to Combat Type 2 Diabetes in India
-
Novo Nordisk Slashes US Prices for Semaglutide Medicines
Google News